{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:13:55Z","timestamp":1781914435743,"version":"3.54.5"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00685","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:31:49Z","timestamp":1590553909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia"],"prefix":"10.3389","volume":"10","author":[{"given":"Hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ting","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ge","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Ji","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S2352-3026(17)30052-2","article-title":"Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","volume":"4","author":"Bonaventure","year":"2017","journal-title":"Lancet Haematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt","year":"2015","journal-title":"J Clin Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","author":"Vo","year":"2019","journal-title":"Haematologica."},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","article-title":"CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia","volume":"2","author":"Jiang","year":"2018","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1182\/blood-2016-08-735365","article-title":"An anti-CD3\/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia","volume":"129","author":"Leong","year":"2017","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"102004","DOI":"10.1016\/j.nano.2019.04.007","article-title":"Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia","volume":"20","author":"Lin","year":"2019","journal-title":"Nanomedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9841","DOI":"10.1002\/anie.201405353","article-title":"Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia","volume":"53","author":"Lu","year":"2014","journal-title":"Angewandte Chemie."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1182\/bloodadvances.2018017004","article-title":"Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient","volume":"2","author":"Zhang","year":"2018","journal-title":"Blood Adv."},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1016\/j.vaccine.2006.02.025","article-title":"An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens","volume":"24","author":"Wang","year":"2006","journal-title":"Vaccine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Lowenberg","year":"2011","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2040620719860645","DOI":"10.1177\/2040620719860645","article-title":"Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches","volume":"10","author":"Winer","year":"2019","journal-title":"Ther Adv Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/ijms20143429","article-title":"Targeting tyrosine kinases in acute myeloid leukemia: why, who and how?","volume":"20","author":"Fernandez","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.blre.2019.02.001","article-title":"Cellular immunotherapy for acute myeloid leukemia: how specific should it be?","volume":"35","author":"Lee","year":"2019","journal-title":"Blood Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-017-0505-0","article-title":"Recent developments in immunotherapy of acute myeloid leukemia","volume":"10","author":"Lichtenegger","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41375-019-0387-y","article-title":"Data mining for mutation-specific targets in acute myeloid leukemia","volume":"33","author":"Benard","year":"2019","journal-title":"Leukemia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1200\/EDBK_238687","article-title":"How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy","volume":"39","author":"Heuser","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00685\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:31:52Z","timestamp":1590553912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00685\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":25,"alternative-id":["10.3389\/fonc.2020.00685"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00685","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"article-number":"685"}}